000275938 001__ 275938
000275938 005__ 20250126000532.0
000275938 0247_ $$2doi$$a10.1002/dad2.70050
000275938 0247_ $$2pmid$$apmid:39811699
000275938 0247_ $$2pmc$$apmc:PMC11730075
000275938 0247_ $$2altmetric$$aaltmetric:173120204
000275938 037__ $$aDZNE-2025-00160
000275938 041__ $$aEnglish
000275938 082__ $$a610
000275938 1001_ $$0P:(DE-2719)9001870$$aBlotenberg, Iris$$b0$$eFirst author$$udzne
000275938 245__ $$aModifiable risk factors and symptom progression in dementia over up to 8 years-Results of the DelpHi-MV trial.
000275938 260__ $$aHoboken, NJ$$bWiley$$c2025
000275938 3367_ $$2DRIVER$$aarticle
000275938 3367_ $$2DataCite$$aOutput Types/Journal article
000275938 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737367013_5001
000275938 3367_ $$2BibTeX$$aARTICLE
000275938 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275938 3367_ $$00$$2EndNote$$aJournal Article
000275938 520__ $$aThis study investigated the association between modifiable factors and symptom progression in dementia over up to 8 years.Multilevel growth curve models assessed the role of modifiable risk factors (low education, hearing impairment and its treatment, depression, physical inactivity, diabetes and its treatment, smoking, hypertension and its treatment, obesity, alcohol consumption, social isolation, and visual impairment) on cognitive and functional trajectories in 353 people with dementia.Higher education was associated with higher initial cognitive status but faster decline. Antidiabetic medication was associated with slower cognitive decline, whereas depression and visual impairment were linked to low baseline functioning and faster cognitive decline.Several modifiable risk factors influenced symptom progression. Education initially had a protective effect, whereas depressive symptoms were linked to worse symptom progression. Treatment of comorbidities (diabetes, visual impairment) could have a positive impact on dementia symptoms. Modifiable risk factors are promising targets for tertiary prevention.Modifiable risk factors were associated with symptom progression in dementia over up to 8 years.More education was associated with higher initial cognitive status but faster decline.Depressive symptoms were linked to less favorable symptom progression.Treatment of comorbidities (diabetes, visual impairment) may positively impact the course of symptoms.Modifiable risk factors are promising targets for tertiary prevention.
000275938 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000275938 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000275938 650_7 $$2Other$$aAlzheimer Disease
000275938 650_7 $$2Other$$aactivities of daily living
000275938 650_7 $$2Other$$aanti‐diabetic medication
000275938 650_7 $$2Other$$acognition
000275938 650_7 $$2Other$$acognitive decline
000275938 650_7 $$2Other$$acomorbidities
000275938 650_7 $$2Other$$adepressive symptoms
000275938 650_7 $$2Other$$aeducation
000275938 650_7 $$2Other$$afunctional decline
000275938 650_7 $$2Other$$alifestyle
000275938 650_7 $$2Other$$amedication
000275938 650_7 $$2Other$$avisual impairment
000275938 7001_ $$aWittström, Felix$$b1
000275938 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b2$$udzne
000275938 7001_ $$0P:(DE-2719)9001238$$aPlaten, Moritz$$b3$$udzne
000275938 7001_ $$0P:(DE-2719)2810631$$aWucherer, Diana$$b4$$udzne
000275938 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b5$$udzne
000275938 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b6$$udzne
000275938 7001_ $$0P:(DE-2719)2290613$$aThyrian, Jochen René$$b7$$eLast author$$udzne
000275938 773__ $$0PERI:(DE-600)2832898-X$$a10.1002/dad2.70050$$gVol. 17, no. 1, p. e70050$$n1$$pe70050$$tAlzheimer's & dementia / Diagnosis, assessment & disease monitoring$$v17$$x2352-8729$$y2025
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.docx
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP2.pdf
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160.pdf$$yOpenAccess
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.doc
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.odt
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP1.pdf
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160%20SUP2.pdf?subformat=pdfa$$xpdfa
000275938 8564_ $$uhttps://pub.dzne.de/record/275938/files/DZNE-2025-00160.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000275938 909CO $$ooai:pub.dzne.de:275938$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000275938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001870$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000275938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000275938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001238$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000275938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000275938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000275938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000275938 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2290613$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000275938 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000275938 9141_ $$y2025
000275938 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
000275938 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-31
000275938 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZH DEMENT-DADM : 2022$$d2024-12-31
000275938 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000275938 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-31$$wger
000275938 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:09:24Z
000275938 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:09:24Z
000275938 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-31
000275938 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
000275938 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000275938 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:09:24Z
000275938 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-31
000275938 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZH DEMENT-DADM : 2022$$d2024-12-31
000275938 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
000275938 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
000275938 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x0
000275938 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x1
000275938 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x2
000275938 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x3
000275938 980__ $$ajournal
000275938 980__ $$aVDB
000275938 980__ $$aUNRESTRICTED
000275938 980__ $$aI:(DE-2719)1510800
000275938 980__ $$aI:(DE-2719)5000067
000275938 980__ $$aI:(DE-2719)1510600
000275938 980__ $$aI:(DE-2719)1510100
000275938 9801_ $$aFullTexts